138 related articles for article (PubMed ID: 19699511)
1. Thrombin-activatable fibrinolysis inhibitor genetic polymorphisms as markers of the type of acute coronary syndrome.
Tàssies D; Roqué M; Monteagudo J; Martorell T; Sionis A; Arzamendi D; Heras M; Reverter JC
Thromb Res; 2009 Nov; 124(5):614-8. PubMed ID: 19699511
[TBL] [Abstract][Full Text] [Related]
2. [Study on the association of thrombin activatable fibrinolysis inhibitor and the Thr325Ile and Thr147Ala polymorphisms of its encoding gene CPB2 in patients with coronary heart disease].
Xu CW; Wang LL; Wu XB; Zhao JJ; Du YM; Jiang CY
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Aug; 25(4):438-42. PubMed ID: 18683146
[TBL] [Abstract][Full Text] [Related]
3. Plasma TAFI and soluble CD40 ligand do not predict reperfusion following thrombolysis for acute myocardial infarction.
Cruden NL; Graham C; Harding SA; Ludlam CA; Fox KA; Newby DE
Thromb Res; 2006; 118(2):189-97. PubMed ID: 16055173
[TBL] [Abstract][Full Text] [Related]
4. Association between the Thr325Ile polymorphism of the thrombin-activatable fibrinolysis inhibitor and stroke in the Ludwigshafen Risk and Cardiovascular Health Study.
Kozian DH; Lorenz M; März W; Cousin E; Mace S; Deleuze JF
Thromb Haemost; 2010 May; 103(5):976-83. PubMed ID: 20216989
[TBL] [Abstract][Full Text] [Related]
5. Genetic variation in thrombin-activatable fibrinolysis inhibitor (TAFI) is associated with the risk of splanchnic vein thrombosis.
de Bruijne EL; Darwish Murad S; de Maat MP; Tanck MW; Haagsma EB; van Hoek B; Rosendaal FR; Janssen HL; Leebeek FW;
Thromb Haemost; 2007 Feb; 97(2):181-5. PubMed ID: 17264944
[TBL] [Abstract][Full Text] [Related]
6. Predictive factors of recurrent angina after acute coronary syndrome: the global registry acute coronary events from China (Sino-GRACE).
Zhao FH; Chen YD; Song XT; Pan WQ; Jin ZN; Yuan F; Li YB; Ren F; Lü SZ;
Chin Med J (Engl); 2008 Jan; 121(1):12-6. PubMed ID: 18208658
[TBL] [Abstract][Full Text] [Related]
7. Platelet glycoprotein IIb HPA-3 polymorphism and acute coronary syndromes.
Lekakis J; Bisti S; Tsougos E; Papathanassiou A; Dagres N; Ikonomidis I; Soteriadou E; Tselepis AD; Goudevenos J; Kremastinos DT
Int J Cardiol; 2008 Jun; 127(1):46-50. PubMed ID: 17561290
[TBL] [Abstract][Full Text] [Related]
8. Fibrinolytic status in acute coronary syndromes: evidence of differences in relation to clinical features and pathophysiological pathways.
Shantsila E; Montoro-García S; Tapp LD; Apostolakis S; Wrigley BJ; Lip GY
Thromb Haemost; 2012 Jul; 108(1):32-40. PubMed ID: 22538774
[TBL] [Abstract][Full Text] [Related]
9. TAFI activity and antigen plasma levels are not increased in acute coronary artery disease patients admitted to a coronary care unit.
Paola Cellai A; Antonucci E; Alessandrello Liotta A; Fedi S; Marcucci R; Falciani M; Giglioli C; Abbate R; Prisco D
Thromb Res; 2006; 118(4):495-500. PubMed ID: 16318869
[TBL] [Abstract][Full Text] [Related]
10. Fibrinolytic inhibitor levels and polymorphisms in Behçet disease and their association with thrombosis.
Ricart JM; Ramón LA; Vayá A; España F; Santaolaria ML; Todolí J; Castelló R; Fontcuberta J; Estellés A
Br J Haematol; 2008 May; 141(5):716-9. PubMed ID: 18341631
[TBL] [Abstract][Full Text] [Related]
11. Association of genotypes of thrombin-activatable fibrinolysis inhibitors with thrombotic microangiopathies--a pilot study.
Sucker C; Hetzel GR; Farokhzad F; Dahhan F; Schmitz M; Kurschat C; Grabensee B; Maruhn-Debowski B; Zotz R; Scharf R
Nephrol Dial Transplant; 2007 May; 22(5):1347-50. PubMed ID: 17327284
[TBL] [Abstract][Full Text] [Related]
12. Different metabolic correlations of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 in non-obese type 2 diabetic patients.
Kitagawa N; Yano Y; Gabazza EC; Bruno NE; Araki R; Matsumoto K; Katsuki A; Hori Y; Nakatani K; Taguchi O; Sumida Y; Suzuki K; Adachi Y
Diabetes Res Clin Pract; 2006 Aug; 73(2):150-7. PubMed ID: 16458385
[TBL] [Abstract][Full Text] [Related]
13. Association of TAFI gene polymorphisms with severity of coronary stenosis in stable coronary artery disease.
Rattanawan C; Komanasin N; Settasatian N; Settasatian C; Kukongviriyapan U; Intharapetch P; Senthong V
Thromb Res; 2018 Nov; 171():171-176. PubMed ID: 30321704
[TBL] [Abstract][Full Text] [Related]
14. Plasma thrombin-activatable fibrinolysis inhibitor levels and its Thr325Ile polymorphism in breast cancer.
Chengwei X; Xiaoli M; Yuan Z; Li P; Shengjiang W; Chao Y; Yunshan W
Blood Coagul Fibrinolysis; 2013 Oct; 24(7):698-703. PubMed ID: 23624357
[TBL] [Abstract][Full Text] [Related]
15. The effect of genetic variants in the thrombin activatable fibrinolysis inhibitor (TAFI) gene on TAFI-antigen levels, clot lysis time and the risk of venous thrombosis.
Martini CH; Brandts A; de Bruijne EL; van Hylckama Vlieg A; Leebeek FW; Lisman T; Rosendaal FR
Br J Haematol; 2006 Jul; 134(1):92-4. PubMed ID: 16803573
[TBL] [Abstract][Full Text] [Related]
16. [Inflammation study in unstable angina and myocardial infarction without ST segment elevation. Value of ultra-sensitive C-reactive protein].
Borrás Pallé S; Gómez Martínez E; Romero Rodrigo A; Campos Ferrer C; Molina E; Valentín Segura V
An Med Interna; 2002 Jun; 19(6):283-8. PubMed ID: 12152386
[TBL] [Abstract][Full Text] [Related]
17. Thrombin activatable fibrinolysis inhibitor activation peptide shows association with all major subtypes of ischemic stroke and with TAFI gene variation.
Ladenvall C; Gils A; Jood K; Blomstrand C; Declerck PJ; Jern C
Arterioscler Thromb Vasc Biol; 2007 Apr; 27(4):955-62. PubMed ID: 17272741
[TBL] [Abstract][Full Text] [Related]
18. Soluble CD40 ligand, plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor-1-antigen in normotensive type 2 diabetic subjects without diabetic complications. Effects of metformin and rosiglitazone.
Yener S; Comlekci A; Akinci B; Demir T; Yuksel F; Ozcan MA; Bayraktar F; Yesil S
Med Princ Pract; 2009; 18(4):266-71. PubMed ID: 19494532
[TBL] [Abstract][Full Text] [Related]
19. Plasma thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 levels in inflammatory bowel disease.
Koutroubakis IE; Sfiridaki A; Tsiolakidou G; Coucoutsi C; Theodoropoulou A; Kouroumalis EA
Eur J Gastroenterol Hepatol; 2008 Sep; 20(9):912-6. PubMed ID: 18794606
[TBL] [Abstract][Full Text] [Related]
20. Thrombin activatable fibrinolysis inhibitor and clot lysis time in pregnant patients with antiphospholipid syndrome: relationship with pregnancy outcome and thrombosis.
Martinez-Zamora MA; Tassies D; Carmona F; Espinosa G; Cervera R; Reverter JC; Balasch J
Am J Reprod Immunol; 2009 Dec; 62(6):381-9. PubMed ID: 19895374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]